In GBM and SARC, SHOX2 expressions showed negative relation with the ICP genes, indicating that patients with high SHOX2 expression might respond poorly to immunotherapies targeting ICP genes in GBM and SARC. The gene discussed is SHOX2; the disease is glioblastoma.